Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...
TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...
Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target cut by research analysts at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The ...
Regeneron Pharmaceuticals Inc. closed 44.20% short of its 52-week high of $1,211.20, which the company reached on August 27th ...
ABC 7 New York on MSN5d
Passionate Long Island senior selected as Regeneron finalist for pancreatic cancer researchEmma Wen, a senior at Great Neck North High School, is researching more effective ways to fight pancreatic cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback